Filing Flows

Filing Flows › Companies › Sight Sciences › Cash flow

Sight Sciences cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$2.5M in Q3 2026 · −$16.9M over twelve months

Operating cash flow−$2.4M
Capital spending−$68K
Free cash flow−$2.5M
Cash conversion cycle144 days

Analysis

In Q3 2026, Sight Sciences generated −$2.4M of operating cash flow and spent $68K on capital projects, leaving free cash flow of −$2.5M. That is $6.4M more than in Q3 2025 (−$8.9M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$16.9M; the largest uses were operating cash flow ($16.9M); besides operations, cash came from shares issued ($1.2M), other financing ($781K); the cash balance fell by $15.0M.

Operating cash flow was −$2.4M against net income of −$6.8M. The largest differences: stock-based pay +$2.9M, receivables −$2.1M, employee-related liabilities +$1.8M.

Its cash conversion cycle was 144 days (receivables 46 + inventory 160 − payables 61).

Free cash flow

Sight Sciences: free cash flow by quarterSight Sciences: free cash flow by quarter−$3.6MQ4 2024−$11.6MQ1 2025−$7.8MQ2 2025−$8.9MQ3 2025−$1.7MQ4 2025−$7.1MQ1 2026−$5.7MQ2 2026−$2.5MQ3 2026
Operating cash flow less capital spending.
Sight Sciences: operating cash flow against capital spendingSight Sciences: operating cash flow against capital spendingOperating cash flowCapital spending−$3.5M$137KQ4 2024−$11.6M$0Q1 2025−$7.5M$210KQ2 2025−$8.7M$170KQ3 2025−$1.8M−$156KQ4 2025−$7.0M$60KQ1 2026−$5.7M$19KQ2 2026−$2.4M$68KQ3 2026
Latest (Q3 2026): Operating cash flow −$2.4M, Capital spending $68K.

Capital allocation, year by year

Sight Sciences: where the cash came from (up) and went (down), by fiscal yearSight Sciences: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedCapital spendingFY2021: Operating cash flow −$52.5MFY2021: Shares issued $257MFY2021: Capital spending −$813K$257MFY2021FY2022: Operating cash flow −$76.0MFY2022: Shares issued $576KFY2022: Capital spending −$970K$576KFY2022FY2023: Operating cash flow −$47.2MFY2023: Shares issued $395KFY2023: Capital spending −$791K$395KFY2023FY2024: Operating cash flow −$22.4MFY2024: Shares issued $255KFY2024: Capital spending −$385K$255KFY2024FY2025: Operating cash flow −$29.7MFY2025: Shares issued $1.1MFY2025: Capital spending −$224K$1.1MFY2025
Over these 5 years operating cash flow totalled −$228M; the largest uses were operating cash flow ($228M) and capital spending ($3.2M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$77.4M
Debt$48.4M
Net cash$29.0M
Due within a year$12.1M
Cash runway4.6 years

Sight Sciences is burning cash: its operations consume cash, a free cash flow of −$16.9M a year at the current rate against $77.4M of cash and investments: a runway of about 4.6 years; $12.1M of debt also comes due within a year, which the cash covers before any new financing.

Sight Sciences: debt maturities by year (FY2025)Sight Sciences: debt maturities by year (FY2025)$23.7MYear 2$16.3MYear 3
Principal due in each year as disclosed in the annual report, against $77.4M of cash and investments now.

Where the cash came from and went

Sight Sciences: sources (+) and uses (−) of cash, Q3 2026Sight Sciences: sources (+) and uses (−) of cash, Q3 2026Operating cash flow−$2.4MCash drawn (+) / kept (−)$2.4MShares issued$123KCapital spending−$68KOther financing−$4K
Sight Sciences: sources (+) and uses (−) of cash, TTM to Q3 2026Sight Sciences: sources (+) and uses (−) of cash, TTM to Q3 2026Operating cash flow−$16.9MCash drawn (+) / kept (−)$15.0MShares issued$1.2MOther financing$781KCapital spending$9K

From profit to cash

Sight Sciences: net income to operating cash flow, Q3 2026Sight Sciences: net income to operating cash flow, Q3 2026Net income−$6.8MDepreciation & amortization$110KStock-based pay$2.9MReceivables−$2.1MInventory−$817KPayables$884KAccrued liabilities$838KEmployee-related liabilities$1.8MOperating cash flow−$2.4M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q3 20264616061144
Q2 20264328776253
Q1 20264624447244
Q4 20254427955268
Q3 20254524165221
Q2 20254418474154
Q1 20255222683195
Q4 20245722755230

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$2.4M−$68K$123K$2.4M−$2.5M
Q2 2026−$5.7M−$19K—$5.2M−$5.7M
Q1 2026−$7.0M−$60K$99K$7.0M−$7.1M
Q4 2025−$1.8M$156K$943K$406K−$1.7M
Q3 2025−$8.7M−$170K$27K$8.9M−$8.9M
Q2 2025−$7.5M−$210K$58K$7.3M−$7.8M
Q1 2025−$11.6M—$63K$11.6M−$11.6M
Q4 2024−$3.5M−$137K$23K−$1.8M−$3.6M

Sight Sciences: income statement and cash flow

Sight Sciences, Q3 2026: revenue $24.9M (+25% year over year), operating margin -24.6%. The chart follows the revenue to costs, profit and cash.

Sight Sciences: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.